Screener
Recursion Pharmaceuticals, Inc. RXRX Retained Earnings Accumulated Deficit
Retained Earnings Accumulated Deficit at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of June 30, 2026 and December 31, 2025; 534,120,235 shares (Class A 533,191,318, Class B — and Exchangeable 928,917) and 528,182,693 shares (Class A 521,831,046, Class B 5,547,334 and Exchangeable 804,313) issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 5 | 5 |
| Additional paid-in capital | 3,211,515 | 3,170,145 |
| Accumulated deficit | (2,324,511) | (2,076,002) |
| Accumulated other comprehensive income | 27,994 | 36,717 |
| Total stockholders’ equity | 915,003 | 1,130,865 |
| Total liabilities and stockholders’ equity | $1,212,668 | $1,474,130 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s retained earnings accumulated deficit?
- Recursion Pharmaceuticals, Inc. (RXRX) reported retained earnings accumulated deficit of -$2.32B in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s retained earnings accumulated deficit changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s retained earnings accumulated deficit decreased by 28.7% year-over-year, from -$1.81B to -$2.32B.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s retained earnings accumulated deficit?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s retained earnings accumulated deficit has grown at a 57.6% compound annual growth rate (CAGR), from -$213.6M to -$2.08B.
- What does retained earnings accumulated deficit mean?
- Retained Earnings Accumulated Deficit as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.
Ask your AI about Recursion Pharmaceuticals, Inc.'s retained earnings accumulated deficit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude